There have been many changes in the treatment landscape of stage II and stage III melanoma over the past decade. This article takes a look at the benefits and risks of some of the novel treatment developments. The author’s research analysis showed an increase in the advancements of early adjuvant therapy which have expanded the treatment landscape for metastatic melanoma, specifically in those with complete resection in stage III.

Read the full article by clicking here.